NCT07782333 A Study Evaluating TRIV-573 in Atopic Dermatitis
| NCT ID | NCT07782333 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Triveni Bio |
| Condition | Atopic Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-09-09 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 90 participants in total. It began in 2026-09-09 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Eligibility Criteria
Inclusion Criteria: * Has Atopic Dermatitis. * Has moderate to severe, active and symptomatic atopic dermatitis. Exclusion Criteria: * Severe or uncontrolled medical conditions. * Use of prohibited medications within stated washout periods.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07782333 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07782333 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07782333 currently recruiting?
Yes, NCT07782333 is actively recruiting participants. Contact the research team at clinicaltrials@triveni.bio for enrollment information.
Where is the NCT07782333 trial being conducted?
This trial is being conducted at Fountain Valley, United States, Los Angeles, United States, Boca Raton, United States, Miami, United States and 11 additional locations.
Who is sponsoring the NCT07782333 clinical trial?
NCT07782333 is sponsored by Triveni Bio. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.